Kate Dellorusso, an analyst from LifeSci Capital, maintained the Buy rating on Soleno Therapeutics. The associated price target remains the same with $110.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kate Dellorusso’s rating is based on the potential synergy between Soleno Therapeutics’ Vykat and future combination therapies. The preliminary data from Rhythm Therapeutics’ Phase 2a trial highlights the potential benefits of Vykat, particularly in patients who are not eligible for other treatments due to conditions like diabetes and significant baseline edema. The involvement of a leading key opinion leader (KOL) and the observed benefits in certain patients using Vykat underscore its potential in addressing specific patient needs.
Despite the small sample size and mixed results in the trial, there is optimism about the full dataset expected in 2026, which could provide a clearer understanding of the therapeutic benefits of setmelanotide both as a monotherapy and in combination with Vykat. The current findings suggest that patient segmentation in Prader-Willi syndrome (PWS) is likely, rather than a one-size-fits-all approach, which could position Soleno Therapeutics favorably in a niche market segment.